Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Auersperg Marija) .

1 - 10 / 18
First pagePrevious page12Next pageLast page
1.
Schedule-dependency of doxorubicin and vinblastine in EAT tumours in mice
Marija Auersperg, Ana Pogačnik, Veronika Kloboves-Prevodnik, Gregor Serša, Maja Čemažar, 2006, original scientific article

Abstract: Background. Antitumour schedule-dependency of the doxorubicin and vinblastine combination was explored. Materials and methods. Intraperitoneal Ehrlich ascites tumours (EAT) syngeneic to CBA mice were treated with vinblastine ar doxorubicin alone, or in combined treatment schedules. Results. Combinations of doxorubicin and vinblasfine administered at 48-h, but not at 24-h interval,regardless of the sequence of drugs, significantly reduced the numberof tumour cells in the ascites in corrtparison with all other treatments. In the combined treatment schedules, the predominant morphologicalchanges as well as DNA distribution pattern were dependent on thefirst drug applied. Regardless of the sequence of the drugs, median survival times of animals did not significantly differ between the treatment groups. Conclusions. The effect of combination of vinblastine and doxorubicin is schedule-dependent. The time interval, but not the sequence of drugs seems to be crucial for the observed effect. The data from preclinical studies are important for planning combined treatment schedules in clinical setting.
Published in DiRROS: 15.02.2024; Views: 78; Downloads: 15
.pdf Full text (250,21 KB)

2.
Antitumor effectiveness of bleomycin on SA-1 tumor after pretreatment with vinblastine
Maja Čemažar, Marija Auersperg, Gregor Serša, 2000, original scientific article

Abstract: In our previous study, vinblastine (VLB) was shown to increase the plasma membrane fluidity. This effect of VLB might be exploited for better transport of drugs through the plasma membrane. The aim of the present study was to determine whether pretreatment with VLB can increase the cytotoxic effect of BLM on intraperitoneal SA-1 tumors in mice. Materials and methods. BLM and VLBwere used as single agents or in various combinations, i.e. BLM injected 24h before VLB or vice-versa, VLB injected 24 h before BLM. Cell and animal survival together with DNA histograms were the end-points used to determine the effect of these combined treatments. Results. Both drugs, either as singletreatment or in different combined therapy schedules reduced significantly the number of cells in peritoneal lavage, compared to control, saline treated animals. The combination of VLB, followed by BLM after 24 h reduced significantly the number of cells in peritoneal lavage, compared to the treatment in which BLM was followed by VLB or to the treatment with singledrugs alone. Median survival time of mice treated with VLB alone, BLM alone and combination of both drugs was significantly prolonged compared to the control untreated mice. When VLB and BLM were combined, both treatment combinations were more effective than monochemotherapies with VLB or BLM. The best results were obtained when VLB was followed by BLM after 24 h. The DNA histogram of cells treated with VLB showed a decreased number of cells in S phase and an increased number of cells with DNA values greater than in G2M compartment compared to the control untreated cells. BLM in the dosage used inthese experiments did not affect the progression of cells through cell cycle. Both combinations of VLB and BLM produced similar cell kinetic effect as VLB alone. Conclusion. (Abstract truncated at 2000 characters.)
Published in DiRROS: 23.01.2024; Views: 123; Downloads: 27
.pdf Full text (499,47 KB)

3.
Vinblastine increases antitumor effectiveness of bleomycin
Maja Čemažar, Marija Auersperg, Gregor Serša, 1997, original scientific article

Abstract: In our previous vinblastine (VELBE) was shown to increase the plasma membrane fluidity. This effect of VELBE might be expolited for better transport of drugs through the plasma membrane. Bleomycin (BLM) is a highly cytotoxic drug when present inside the cells but has a hampered transport through the plasma membrane. The aim of the present study was to determine whether pretreatment with VELBE can increase the effect of BLM on intraperitoneal SA-1 tumors in mice. BLM and VELBE were used as single agents or in various combinations, i.e. VELBE and BLM injected simultanously, BLM injected 24 h before VELBE or VELBE injected 24 h before BLM. Mice survival was the end-point used for determining the effect of this combined treatments. VELBE and BLM as a single treatment significantly prolonged median survival time of study animals compared to controls. Furthermore, when VELBE and BLM were combined, all threetested combinations were more effective than VELBE or BLM as single treatments. The effect on animal survival was equal when VELBE was given 24 h after or simultanously with BLM. The longest survival, however was obtained when VELBE was injected 24 h before BLM. From these results we can conclude that the underlying mechanisms for more than additive effect of VELBE and BLM when VELBE was given 24 h before BLM could be attributed to an increased membrane fluidity, possibly in combination with a cell kinetic effect.
Published in DiRROS: 18.01.2024; Views: 114; Downloads: 25
.pdf Full text (1,28 MB)

4.
5.
6.
7.
8.
9.
10.
Chemotherapy with synchronization in advanced cancer of the head and neck
Marija Auersperg, Erika Šoba, Marjan Erjavec, Marija Us-Krašovec, Marija Fidler-Jenko, 1976, original scientific article

Published in DiRROS: 13.09.2023; Views: 189; Downloads: 60
.pdf Full text (907,21 KB)

Search done in 0.27 sec.
Back to top